Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis

Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis

Abstract Background While immunotherapy combined with chemotherapy (Chemo-IO) is generally recognized for providing superior outcomes compared to monotherapy (mono-IO), it is associated with a higher incidence of treatment-related adverse events (TRAEs), which may lead to treatment discontinuation....

Full description

Bibliographic Details
Main Authors: Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Adverse drug event
Chemotherapy
Immunotherapy
Network meta-analysis
Treatment-related adverse event
Online Access:https://doi.org/10.1186/s12885-024-11897-4

Internet

https://doi.org/10.1186/s12885-024-11897-4

Similar Items